Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotion Pathology

San Francisco, CA (March 7, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is proud to announce its partnership with the International Society of Equine Locomotion Pathology (ISELP) by joining their team of Global Sponsors starting in 2017. The partnership with ISELP is part of […]

Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results

San Francisco, CA (March 1, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN) (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2016. “We are very pleased with the progress of Mirataz™ and Zimeta™, including the recently announced approval […]

Kindred Biosciences to Announce Fourth Quarter and Year-End 2016 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 1, 2017 San Francisco, CA (February 21, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and […]

Kindred Biosciences Receives Early Approval of Effectiveness Technical Section from FDA for Mirataz New Animal Drug Application

San Francisco, CA (February 6, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced it has received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration’s Center for Veterinary Medicine for Mirataz™ (mirtazapine transdermal ointment) approving the technical section. […]

Kindred Biosciences to Present Zimeta Pivotal Data at the 62nd Annual American Association of Equine Practitioners Convention

San Francisco, CA (November 29, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Emily Sundman, DVM, Clinical Development Scientist for KindredBio, will present pivotal effectiveness data for Zimeta™ (dipyrone injection) at the American Association of Equine Practitioners (AAEP) Convention in Orlando, FL […]